It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis.
The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial’ (ABSTRACT NUMBER: 1444) was presented at the 2020 ACR Convergence, 5-9 November.
- What are the arguments for and against the treat-to-target (T2T) strategy in the management of axial spondyloarthritis? (0:05)
- Could you tell us a little about the design of the TICOSPA trial? (1:51)
- What were the findings of this study in terms of primary outcomes and safety of the T2T strategy? (2:55)
- What are the implications of these findings for clinical practice? (4:10)
Disclosures: Anna Moltó has acted as a Consultant/Speaker for Abbvie, BMS, Eli Lilly, Novartis, UCB and Gilead.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Axial Spondyloarthritis
Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis
It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment. ‘NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Marina Magrey, ACR 2020 – Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study
It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!